Yang Chenli, Ren Guangshu, Yang Qingqing
Department of Cardiothoracic Surgery, Gansu Provincial Hospital of TCM, Lanzhou, China.
Department of Thoracic Surgery, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, China.
Front Surg. 2023 Jan 9;9:1094973. doi: 10.3389/fsurg.2022.1094973. eCollection 2022.
The predictive role of modified Glasgow prognostic score (mGPS) for long-term survival in several types of cancers has been well manifested. We supposed that preoperative mGPS might also be associated with long-term survival of operated non-small cell lung cancer (NSCLC) patients. The aim of this meta-analysis was to identify the prognostic value of preoperative mGPS in surgical NSCLC patients.
The PubMed, Web of Science, EMBASE and CNKI databases were searched for relevant studies up to November 7, 2022. The primary and secondary outcomes were overall survival (OS) and disease-free survival (DFS), respectively. The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined.
A total of 3,803 patients from 11 studies were enrolled and analyzed. The combined results demonstrated elevated preoperative mGPS was significantly related to poorer OS (HR = 2.11, 95% CI: 1.83-2.44, < 0.001) and DFS (HR = 1.70, 95% CI: 1.42-2.03, < 0.001). Subgroup analysis for the OS further identified the predictive role of elevated preoperative mGPS for worse OS in NSCLC.
Preoperative mGPS was significantly associated with prognosis in NSCLC and patients with elevated preoperative mGPS experienced poorer long-term survival.
改良格拉斯哥预后评分（mGPS）在多种癌症长期生存中的预测作用已得到充分体现。我们推测术前mGPS可能也与接受手术的非小细胞肺癌（NSCLC）患者的长期生存相关。本荟萃分析的目的是确定术前mGPS在接受手术的NSCLC患者中的预后价值。
检索PubMed、Web of Science、EMBASE和中国知网数据库，截至2022年11月7日的相关研究。主要和次要结局分别为总生存期（OS）和无病生存期（DFS）。合并风险比（HR）和95%置信区间（CI）。
共纳入并分析了来自11项研究的3803例患者。合并结果显示，术前mGPS升高与较差的OS（HR = 2.11，95% CI：1.83 - 2.44，P < 0.001）和DFS（HR = 1.70，95% CI：1.42 - 2.03，P < 0.001）显著相关。OS的亚组分析进一步确定了术前mGPS升高对NSCLC患者较差OS的预测作用。
术前mGPS与NSCLC的预后显著相关，术前mGPS升高的患者长期生存较差。
Zotero 插件
